Strides Arcolab and Eli Lilly collaborate to expand cancer drug delivery
The collaboration between the two drug firms will focus on expanding the delivery of cancer medicines in the emerging markets.
Bengaluru, December 5, 2012: Drug firms Strides Arcolab and Eli Lilly have joined hands in order to expand the delivery of cancer medicines in the emerging markets. As per the agreement between the two firms, Eli Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides Arcolab, based in Bengaluru.
It is worth noting there that Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these products in various emerging markets across the globe. In addition to the 10 medicines included as part of the agreement, Eli Lilly has the independence to add additional high-quality branded generic oncology products to the portfolio in the coming times.
“Cancer medicines of the highest quality continue to be an unmet need in many markets around the world. Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets,” said Mr Jacques Tapiero, Lilly Senior Vice-President and President (emerging markets division), Eli Lilly.
“We are delighted to partner with Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly’s strong global presence in key markets,” said Mr Arun Kumar, Founder & Group CEO of Strides Arcolab.